|
Autosomal Recessive Osteopetrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Red cell carbonic anhydrase isoenzyme activities (HCA-I and HCA-II) were quantitated in blood hemolysates of two female siblings affected with autosomal recessive osteopetrosis in addition to family members who were both obligate and potential heterozygotes as well as normal controls.
|
3933860 |
1985 |
|
Colon Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To elucidate the mechanism of NMF-mediated radiosensitization, we examined the effects of this agent on gamma-ray-induced DNA double-strand breaks and micronuclei in two cell lines, clone A (human colon carcinoma) and HCA-1 (murine hepatocarcinoma).
|
2756107 |
1989 |
|
Liver carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
To elucidate the mechanism of NMF-mediated radiosensitization, we examined the effects of this agent on gamma-ray-induced DNA double-strand breaks and micronuclei in two cell lines, clone A (human colon carcinoma) and HCA-1 (murine hepatocarcinoma).
|
2756107 |
1989 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
A tumor growth delay assay was performed using murine syngeneic tumors; one radioresistant tumor, HCa-I and one radiosensitive tumor, MCa-K.
|
20657160 |
2010 |
|
Neoplasms
|
0.070 |
AlteredExpression
|
group |
BEFREE |
Examination of tumors resected from patients with pancreatic cancer indicated that 94% (148 of 158) expressed high levels of GPR81.
|
24928781 |
2014 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
GPR81 is a lactate receptor recently identified in adipose and muscle cells that has not been investigated in cancer.
|
24928781 |
2014 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Cells in which GPR81 was silenced showed a dramatic decrease in growth and metastasis.
|
24928781 |
2014 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
GPR81 is a lactate receptor recently identified in adipose and muscle cells that has not been investigated in cancer.
|
24928781 |
2014 |
|
Pancreatic carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In vivo, GPR81 expression levels correlated with the rate of pancreatic cancer tumor growth and metastasis.
|
24928781 |
2014 |
|
Malignant neoplasm of pancreas
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
In vivo, GPR81 expression levels correlated with the rate of pancreatic cancer tumor growth and metastasis.
|
24928781 |
2014 |
|
hepatitis immune
|
0.010 |
Biomarker
|
disease |
BEFREE |
The administration of lactate reduced inflammation and organ injury in mice with immune hepatitis; this reduction required Gpr81 dependence in vivo.
|
24657625 |
2014 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
Overall, these findings identify GPR81 as a tumor-promoting receptor in breast cancer progression and suggest a novel mechanism that regulates GPR81-dependent activation of the PI3K/Akt signaling axis in tumor microenvironment.
|
27765922 |
2016 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
These sulfonamides were investigated as inhibitors of the human carbonic anhydrase (hCA, EC 4.2.1.1) isoforms hCA I and II (cytosolic isozymes), as well as hCA IX and XII (trans-membrane, tumor-associated enzymes).
|
26875933 |
2016 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Overall, these findings identify GPR81 as a tumor-promoting receptor in breast cancer progression and suggest a novel mechanism that regulates GPR81-dependent activation of the PI3K/Akt signaling axis in tumor microenvironment.
|
27765922 |
2016 |
|
Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Overall, these findings identify GPR81 as a tumor-promoting receptor in breast cancer progression and suggest a novel mechanism that regulates GPR81-dependent activation of the PI3K/Akt signaling axis in tumor microenvironment.
|
27765922 |
2016 |
|
Glaucoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Some of these sulfonamides showed effective inhibitory action (in the nanomolar range) against the cytosolic isoform hCA II and the transmembrane, tumor-associated one hCA IX, making them interesting candidates for preclinical evaluation in glaucoma or various tumors in which the two enzymes are involved. hCA I and IV were on the other hand less inhibited by these sulfonamides, with inhibition constants in the micromolar range.
|
28161252 |
2017 |
|
Neoplasms
|
0.070 |
Biomarker
|
group |
BEFREE |
GPR81 and GPR91 are tumor promoters, and increased production of lactate and succinate as their agonists drives tumorigenesis by enhancing signaling via these two receptors.
|
28512002 |
2017 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
As such, these three metabolite receptors play a critical role in cancer and represent a new class of drug targets with selective antagonists of GPR81 and GPR91 for cancer treatment and agonists of GPR109A for cancer prevention.
|
28512002 |
2017 |
|
Malignant Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
The lactate receptor, also known as hydroxycarboxylic acid receptor 1 (HCAR1/GPR81), plays a vital role in cancer biology.
|
29151072 |
2017 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Recently, hydroxycarboxylic acid receptor 1 (HCAR1) was shown to drive lactate-dependent enhancement of cell survival and metastasis in pancreatic and breast cancers.
|
28258841 |
2017 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Recently, HCAR1 was reported to enhance metastasis, cell growth, and survival of pancreatic, breast, and cervical cancer cells.
|
29151072 |
2017 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Through its transporters (MCTs) and receptor (GPR81), lactic acid plays a key role in multiple cellular processes, including energy regulation, immune tolerance, memory formation, wound healing, ischemic tissue injury, and cancer growth and metastasis.
|
29021365 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
The lactate receptor, also known as hydroxycarboxylic acid receptor 1 (HCAR1/GPR81), plays a vital role in cancer biology.
|
29151072 |
2017 |
|
Primary malignant neoplasm
|
0.050 |
Biomarker
|
group |
BEFREE |
As such, these three metabolite receptors play a critical role in cancer and represent a new class of drug targets with selective antagonists of GPR81 and GPR91 for cancer treatment and agonists of GPR109A for cancer prevention.
|
28512002 |
2017 |
|
Malignant neoplasm of breast
|
0.020 |
Biomarker
|
disease |
BEFREE |
Recently, hydroxycarboxylic acid receptor 1 (HCAR1) was shown to drive lactate-dependent enhancement of cell survival and metastasis in pancreatic and breast cancers.
|
28258841 |
2017 |